Overview

Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination

Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide emergency treatment of adult and pediatric patients: - Following a fluorouracil or capecitabine overdose regardless of the presence of symptoms or - Who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous systems, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.
Details
Lead Sponsor:
Wellstat Therapeutics
Treatments:
Antidotes
Capecitabine
Fluorouracil